CLC number:
On-line Access: 2024-08-27
Received: 2023-10-17
Revision Accepted: 2024-05-08
Crosschecked: 2021-03-16
Cited: 0
Clicked: 5286
Citations: Bibtex RefMan EndNote GB/T7714
Shijin YUAN, Yong PAN, Yan XIA, Yan ZHANG, Jiangnan CHEN, Wei ZHENG, Xiaoping XU, Xinyou XIE, Jun ZHANG. Development and validation of an individualized nomogram for early prediction of the duration of SARS-CoV-2 shedding in COVID-19 patients with non-severe disease[J]. Journal of Zhejiang University Science B, 2021, 22(4): 318-329.
@article{title="Development and validation of an individualized nomogram for early prediction of the duration of SARS-CoV-2 shedding in COVID-19 patients with non-severe disease",
author="Shijin YUAN, Yong PAN, Yan XIA, Yan ZHANG, Jiangnan CHEN, Wei ZHENG, Xiaoping XU, Xinyou XIE, Jun ZHANG",
journal="Journal of Zhejiang University Science B",
volume="22",
number="4",
pages="318-329",
year="2021",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B2000608"
}
%0 Journal Article
%T Development and validation of an individualized nomogram for early prediction of the duration of SARS-CoV-2 shedding in COVID-19 patients with non-severe disease
%A Shijin YUAN
%A Yong PAN
%A Yan XIA
%A Yan ZHANG
%A Jiangnan CHEN
%A Wei ZHENG
%A Xiaoping XU
%A Xinyou XIE
%A Jun ZHANG
%J Journal of Zhejiang University SCIENCE B
%V 22
%N 4
%P 318-329
%@ 1673-1581
%D 2021
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B2000608
TY - JOUR
T1 - Development and validation of an individualized nomogram for early prediction of the duration of SARS-CoV-2 shedding in COVID-19 patients with non-severe disease
A1 - Shijin YUAN
A1 - Yong PAN
A1 - Yan XIA
A1 - Yan ZHANG
A1 - Jiangnan CHEN
A1 - Wei ZHENG
A1 - Xiaoping XU
A1 - Xinyou XIE
A1 - Jun ZHANG
J0 - Journal of Zhejiang University Science B
VL - 22
IS - 4
SP - 318
EP - 329
%@ 1673-1581
Y1 - 2021
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B2000608
Abstract: With the number of cases of coronavirus disease-2019 (COVID-19) increasing rapidly, the World Health Organization (WHO) has recommended that patients with mild or moderate symptoms could be released from quarantine without nucleic acid retesting, and self-isolate in the community. This may pose a potential virus transmission risk. We aimed to develop a nomogram to predict the duration of viral shedding for individual COVID-19 patients. This retrospective multicentric study enrolled 135 patients as a training cohort and 102 patients as a validation cohort. Significant factors associated with the duration of viral shedding were identified by multivariate Cox modeling in the training cohort and combined to develop a nomogram to predict the probability of viral shedding at 9, 13, 17, and 21 d after admission. The nomogram was validated in the validation cohort and evaluated by concordance index (C-index), area under the curve (AUC), and calibration curve. A higher absolute lymphocyte count (P=0.001) and lymphocyte-to-monocyte ratio (P=0.013) were correlated with a shorter duration of viral shedding, while a longer activated partial thromboplastin time (P=0.007) prolonged the viral shedding duration. The C-indices of the nomogram were 0.732 (95% confidence interval (CI): 0.685‒0.777) in the training cohort and 0.703 (95% CI: 0.642‒0.764) in the validation cohort. The AUC showed a good discriminative ability (training cohort: 0.879, 0.762, 0.738, and 0.715 for 9, 13, 17, and 21 d; validation cohort: 0.855, 0.758, 0.728, and 0.706 for 9, 13, 17, and 21 d), and calibration curves were consistent between outcomes and predictions in both cohorts. A predictive nomogram for viral shedding duration based on three easily accessible factors was developed to help estimate appropriate self-isolation time for patients with mild or moderate symptoms, and to control virus transmission.
[1]BullardJ, DustK, FunkD, et al., 2020. Predicting infectious severe acute respiratory syndrome coronavirus 2 from diagnostic samples. Clin Infect Dis, 71(10):2663-2666.
[2]ChenRC, LiangWH, JiangM, et al., 2020. Risk factors of fatal outcome in hospitalized subjects with coronavirus disease 2019 from a nationwide analysis in China. Chest, 158(1):97-105.
[3]DeLongER, DeLongDM, Clarke-PearsonDL, 1988. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics, 44(3):837-845.
[4]Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention, 2020. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Chin J Epidemiol, 41(2):145-151 (in Chinese).
[5]GiannisD, ZiogasIA, GianniP, 2020. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. J Clin Virol, 127:104362.
[6]GuanWJ, NiZY, HuY, et al., 2020. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med, 382(18):1708-1720.
[7]HenryBM, de OliveiraMHS, BenoitS, et al., 2020. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med, 58(7):1021-1028.
[8]LiG, FanYH, LaiYN, et al., 2020. Coronavirus infections and immune responses. J Med Virol, 92(4):424-432.
[9]LiLZ, ZhangBH, HeB, et al., 2020. Critical patients with coronavirus disease 2019: risk factors and outcome nomogram. J Infect, 80(6):e37-e38.
[10]LiQ, GuanXH, WuP, et al., 2020. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med, 382(13):1199-1207.
[11]LianJS, CaiH, HaoSR, et al., 2020. Comparison of epidemiological and clinical characteristics of COVID-19 patients with and without Wuhan exposure history in Zhejiang Province, China. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 21(5):369-377.
[12]LiangWH, LiangHR, OuLM, et al., 2020. Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19. JAMA Intern Med, 180(8):1081-1089.
[13]LinAF, HeZB, ZhangS, et al., 2020. Early risk factors for the duration of severe acute respiratory syndrome coronavirus 2 viral positivity in patients with coronavirus disease 2019. Clin Infect Dis, 71(16):2061-2065.
[14]NHC (National Health Commission of the People’s Republic of China), 2020. Clinical diagnosis and treatment guidance of 2019 novel coronavirus (2019-nCoV) caused pneumonia (5th Edition). http://www.nhc.gov.cn/yzygj/s7653p/202002/3b09b894ac9b4204a79db5b8912d4440/files/7260301a393845fc87fcf6dd52965ecb.pdf(in Chinese).
[15]SubramaniamS, ScharrerI, 2018. Procoagulant activity during viral infections. Front Biosci (Landmark Ed), 23:1060-1081.
[16]SunSY, CaiXJ, WangHG, et al., 2020. Abnormalities of peripheral blood system in patients with COVID-19 in Wenzhou, China. Clin Chim Acta, 507:174-180.
[17]TangN, LiDJ, WangX, et al., 2020. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost, 18(4):844-847.
[18]WHO (World Health Organization), 2020a. Clinical management of COVID-19: interim guidance. https://www.who.int/publications/i/item/clinical-management-of-covid-19
[19]WHO, 2020b. Coronavirus disease (COVID-19): situation reports-209. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200816-covid-19-sitrep-209.pdf?sfvrsn= 5dde1ca2_2
[20]WHO, 2020c. Criteria for releasing COVID-19 patients from isolation. https://www.who.int/news-room/commentaries/detail/criteria-for-releasing-covid-19-patients-from-isolation
[21]WHO, 2020d. Laboratory testing of human suspected cases of novel coronavirus (nCoV) infection: interim guidance. https://apps.who.int/iris/bitstream/handle/10665/330374/WHO-2019-nCoV-laboratory-2020.1-eng.pdf
[22]WölfelR, CormanVM, GuggemosW, et al., 2020. Virological assessment of hospitalized patients with COVID-2019. Nature, 581(7809):465-469.
[23]WuCM, ChenXY, CaiYP, et al., 2020. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med, 180(7):934-943.
[24]XiaoAT, TongYX, ZhangS, 2020. Profile of RT-PCR for SARS-CoV-2: a preliminary study from 56 COVID-19 patients. Clin Infect Dis, 71(16):2249-2251.
[25]XuKJ, ChenYF, YuanJ, et al., 2020. Factors associated with prolonged viral RNA shedding in patients with coronavirus disease 2019 (COVID-19). Clin Infect Dis, 71(15):799-806.
[26]YangAP, LiuJP, TaoWQ, et al., 2020. The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients. Int Immunopharmacol, 84:106504.
[27]YangY, ShenCG, LiJX, et al., 2020. Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19. J Allergy Clin Immunol, 146(1):119-127.e4.
[28]ZhaoQW, MengM, KumarR, et al., 2020. Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a systemic review and meta-analysis. Int J Infect Dis, 96:131-135.
[29]ZhengHY, ZhangM, YangCX, et al., 2020. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. Cell Mol Immunol, 17(5):541-543.
[30]ZhengSF, FanJ, YuF, et al., 2020. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January‒March 2020: retrospective cohort study. BMJ, 369:m1443.
[31]ZhouF, YuT, DuRH, et al., 2020. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet, 395(10229):1054-1062.
[32]ZhouYG, FuBQ, ZhengXH, et al., 2020. Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients. Nat Sci Rev, 7(6):998-1002.
[33]ZhouZ, RenLL, ZhangL, et al., 2020. Overly exuberant innate immune response to SARS-CoV-2 infection. SSRN, in press.
[34]ZhuN, ZhangDY, WangWL, et al., 2020. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med, 382(8):727-733.
[35]ZouL, RuanF, HuangM, et al., 2020. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med, 382(12):1177-1179.
Open peer comments: Debate/Discuss/Question/Opinion
<1>